XOMA Corp
XOMA Corp (ticker: XOMAP) is a small-cap biotechnology company (market cap about $420.77M) focused on discovery and development of therapeutic antibodies and related biologics. Investors should know XOMA operates in a high-risk, high-reward segment where clinical trial outcomes, regulatory decisions and partner deals materially affect value. The company may pursue collaborations, licensing and milestone-based revenue rather than steady commercial sales, and could require additional capital to advance programmes, which can dilute existing shareholders. For patient, long-term investors this type of stock can offer exposure to advances in immunology and biologic therapies, but it is important to assess the pipeline stage, cash runway, trial data and management track record. This summary is educational only, not personalised investment advice — values can rise or fall and past performance is not a reliable guide to future returns.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying XOMA Corp's stock as it has significant potential for growth.
Financial Health
XOMA Corp shows strong revenue and cash flow, indicating good financial stability and performance.
Dividend
XOMA Corp's projected dividend yield of 2.12% offers a modest return for investors seeking dividends. If you invested $1000 you would be paid $21.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring XOMAP
Intellectual Property Royalties
Invest in companies that own the rights to valuable ideas, not just physical products. This collection features businesses earning high-margin income from patents, music catalogs, and character franchises — carefully selected by our analysts to give you exposure to the economics of innovation itself.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical milestone watch
Pipeline trial results and regulatory updates can move the share price; stay aware that outcomes are binary and performance can vary.
Technology platform
A strong platform or novel antibody approach can underpin long-term value, though commercial success is not guaranteed and technical hurdles remain.
Partnership potential
Collaborations or licences can derisk programmes and provide milestones, but terms and counterparties influence ultimate value.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
